Cargando…

Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation

Epidermal growth factor receptor (EGFR) overexpression and EGFR-mediated signaling pathway dysregulation have been observed in tumors from patients with various cancers, especially non-small cell lung cancer. Thus, several anti-EGFR drugs have been developed for cancer therapy. For patients with kno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoshi, Hirotaka, Hiyama, Gen, Ishikawa, Kosuke, Inageda, Kiyoshi, Fujimoto, Jiro, Wakamatsu, Ai, Togashi, Takushi, Kawamura, Yoshifumi, Takahashi, Nobuhiko, Higa, Arisa, Goshima, Naoki, Semba, Kentaro, Watanabe, Shinya, Takagi, Motoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355725/ https://www.ncbi.nlm.nih.gov/pubmed/27840973 http://dx.doi.org/10.3892/or.2016.5227

Ejemplares similares

An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids
por: Takahashi, Nobuhiko, et al.
Publicado: (2019)

Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy
por: Takahashi, Nobuhiko, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells
por: Kasahara, Yamato, et al.
Publicado: (2023)

Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues
por: Tamura, Hirosumi, et al.
Publicado: (2018)

Isolation of Reporter Cells That Respond to Vitamin A and/or D Using a piggyBac Transposon Promoter-Trapping Vector System
por: Ishikawa, Kosuke, et al.
Publicado: (2022)

Cadmium Induces the Expression of Grp78, an Endoplasmic Reticulum Molecular Chaperone, in LLC-PK1 Renal Epithelial Cells
por: Liu, Fang, et al.
Publicado: (2006)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Phosphoproteomics-Based Modeling Defines the Regulatory Mechanism Underlying Aberrant EGFR Signaling
por: Tasaki, Shinya, et al.
Publicado: (2010)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

EGFR-dependent phosphorylation of leucine-rich repeat kinase LRRK1 is important for proper endosomal trafficking of EGFR
por: Ishikawa, Kouki, et al.
Publicado: (2012)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma
por: Saito, Yuichi, et al.
Publicado: (2022)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Mallory‐Weise syndrome in a patient treated with EGFR‐TKI
por: Okauchi, Shinichiro, et al.
Publicado: (2017)

Tenascin turns on the EGFR
por: Jegalian, Karin
Publicado: (2001)

Sweeter tumors with EGFR
por: Robinson, Richard
Publicado: (2008)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors
por: Chang, Xiaofei, et al.
Publicado: (2013)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rs8q9qmcspf2beqptvc53koh17